Leo Kager
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Leo Kager has a total of 414 co-authors. Here are the top co-authors by number of shared publications:
- Stefan Bielack
Klinikum Stuttgart – Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Stuttgart, Germany
11 shared publications - Claudia Blattmann
Klinikum Stuttgart – Olgahospital, Stuttgart Cancer Center, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pädiatrie 5 (Onkologie, Hämatologie, Immunologie), Stuttgart, Germany
9 shared publications Matthias Kevric
9 shared publications- Nils Welter
Department of Pediatric Hematology and Oncology Saarland University Hospital, Homburg Saar Germany
9 shared publications - Norbert Graf
University Hospital of Saarland
9 shared publications Benjamin Sorg
8 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 249
Osteosarcoma as a second or later malignancy: Presentation, treatment, and survival of 198 patients from the Cooperative Osteosarcoma Study Group
- 30 October 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 249
Open AccessOsteosarcoma as a second or later malignancy: Presentation, treatment, and survival of 198 patients from the Cooperative Osteosarcoma Study Group
- Top Cited PapersOpen Access
- 7 May 2026
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 45 (2) , 29
New biological insights into osteosarcoma—lessons from single cell sequencing studies
Osteosarcoma (OS), the most frequent primary malignant bone tumor in children and adolescents, is characterized by substantial inter- and intra-tumoral heterogeneity and an immunosuppressive tumor microenvironment (TME), constraining the efficacy of both standard chemotherapy and emerging immunotherapies. Recent advances in single-cell and single-nucleus RNA sequencing (scRNA-seq and snRNA-seq) have enabled high-resolution profiling of OS tumors, revealing diverse malignant, immune, and stromal cell populations. These studies have identified proliferative, inflammatory, and angiogenic tumor states, immunosuppressive myeloid subsets, exhausted T cells, and complex cell–cell communication networks that contribute to tumor progression and immune evasion. However, several challenges constrain the broader application of single-cell approaches in OS. The mineralized structure of bone tissue complicates dissociation into viable single cells, and the rarity of OS limits access to fresh specimens. Most existing datasets are based on small, heterogeneous cohorts and are generated using diverse protocols, which complicate data integration and comparison. Emerging methods are beginning to overcome these barriers. These include snRNA-seq for frozen and archival tissue, improved dissociation protocols for mineralized tumors, and integration with spatial transcriptomics to retain spatial context. Moving forward, combining single-cell transcriptomics with complementary modalities, such as immune repertoire analysis, chromatin accessibility profiling, and spatial proteo-genomics, combined with functional validation, will provide deeper insights into immune dynamics, regulatory mechanisms, and the cellular architecture of the OS TME. This review summarizes the current landscape of single-cell transcriptomics in OS and highlights methodological challenges in single-cell studies in OS tumors, recent biological insights, and their implication for immunotherapies.
- 7 May 2026
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 45 (2) , 29
Top Cited PapersOpen AccessNew biological insights into osteosarcoma—lessons from single cell sequencing studies
Osteosarcoma (OS), the most frequent primary malignant bone tumor in children and adolescents, is characterized by substantial inter- and intra-tumoral heterogeneity and an immunosuppressive tumor microenvironment (TME), constraining the efficacy of both standard chemotherapy and emerging immunotherapies. Recent advances in single-cell and single-nucleus RNA sequencing (scRNA-seq and snRNA-seq) have enabled high-resolution profiling of OS tumors, revealing diverse malignant, immune, and stromal cell populations. These studies have identified proliferative, inflammatory, and angiogenic tumor states, immunosuppressive myeloid subsets, exhausted T cells, and complex cell–cell communication networks that contribute to tumor progression and immune evasion. However, several challenges constrain the broader application of single-cell approaches in OS. The mineralized structure of bone tissue complicates dissociation into viable single cells, and the rarity of OS limits access to fresh specimens. Most existing datasets are based on small, heterogeneous cohorts and are generated using diverse protocols, which complicate data integration and comparison. Emerging methods are beginning to overcome these barriers. These include snRNA-seq for frozen and archival tissue, improved dissociation protocols for mineralized tumors, and integration with spatial transcriptomics to retain spatial context. Moving forward, combining single-cell transcriptomics with complementary modalities, such as immune repertoire analysis, chromatin accessibility profiling, and spatial proteo-genomics, combined with functional validation, will provide deeper insights into immune dynamics, regulatory mechanisms, and the cellular architecture of the OS TME. This review summarizes the current landscape of single-cell transcriptomics in OS and highlights methodological challenges in single-cell studies in OS tumors, recent biological insights, and their implication for immunotherapies.
- Open Access
- 29 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (7) , e70354
The Fate (Outcome) of Clinically Apparent Single Lesion and Oligofocal Nephroblastomatosis Treated According to SIOP/GPOH Protocols for Wilms Tumor
Background: The management of clinically apparent single lesions or oligofocal nephroblastomatosis, a facultative precursor of nephroblastoma, remains debated. Methods: We retrospectively analyzed 37 patients with clinically apparent single or oligofocal nephroblastomatosis (two to three lesions per kidney) among 2347 patients registered between 1993 and 2014 in the SIOP93‐01/GPOH and SIOP2001/GPOH renal tumor studies. Results: Of the 37 patients, 23 had a single lesion, and 14 had oligofocal disease; 65% had a clinically apparent and/or molecularly diagnosed cancer predisposition syndrome, and 27% bilateral involvement. Preoperative chemotherapy was administered to 62%, primary surgery to 32%, and chemotherapy without surgery to 5%. Nephron‐sparing surgery was performed in 71%. In oligofocal cases, preoperative chemotherapy led to significant tumor volume reduction. Prognosis was favorable: 10‐year event‐free, nephroblastoma‐free, and overall survival rates were 77.4%, 80.7%, and 92.0%, respectively. Of 35 patients who underwent definitive surgery, 26 received short postoperative treatment (≤4 weeks) or a watch‐and‐wait approach (W&W). Three patients (11.5%) developed nephroblastoma, two of whom were successfully salvaged. Ten‐year nephroblastoma‐free survival was 74.1%, 90.0%, and 100% for short, W&W, and long postoperative treatment (>4 weeks), respectively. All 12 patients undergoing primary definitive surgery remained nephroblastoma‐free. Conclusion: Short postoperative chemotherapy or W&W is a safe option for patients with single or oligofocal nephroblastomatosis in complete remission, provided they undergo close ultrasound monitoring. The modest relapse risk, manageable with salvage therapy, must be weighed against the toxicity of prolonged treatment, especially in infants. Both primary and delayed surgery are viable strategies.
- 29 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (7) , e70354
Open AccessThe Fate (Outcome) of Clinically Apparent Single Lesion and Oligofocal Nephroblastomatosis Treated According to SIOP/GPOH Protocols for Wilms Tumor
Background: The management of clinically apparent single lesions or oligofocal nephroblastomatosis, a facultative precursor of nephroblastoma, remains debated. Methods: We retrospectively analyzed 37 patients with clinically apparent single or oligofocal nephroblastomatosis (two to three lesions per kidney) among 2347 patients registered between 1993 and 2014 in the SIOP93‐01/GPOH and SIOP2001/GPOH renal tumor studies. Results: Of the 37 patients, 23 had a single lesion, and 14 had oligofocal disease; 65% had a clinically apparent and/or molecularly diagnosed cancer predisposition syndrome, and 27% bilateral involvement. Preoperative chemotherapy was administered to 62%, primary surgery to 32%, and chemotherapy without surgery to 5%. Nephron‐sparing surgery was performed in 71%. In oligofocal cases, preoperative chemotherapy led to significant tumor volume reduction. Prognosis was favorable: 10‐year event‐free, nephroblastoma‐free, and overall survival rates were 77.4%, 80.7%, and 92.0%, respectively. Of 35 patients who underwent definitive surgery, 26 received short postoperative treatment (≤4 weeks) or a watch‐and‐wait approach (W&W). Three patients (11.5%) developed nephroblastoma, two of whom were successfully salvaged. Ten‐year nephroblastoma‐free survival was 74.1%, 90.0%, and 100% for short, W&W, and long postoperative treatment (>4 weeks), respectively. All 12 patients undergoing primary definitive surgery remained nephroblastoma‐free. Conclusion: Short postoperative chemotherapy or W&W is a safe option for patients with single or oligofocal nephroblastomatosis in complete remission, provided they undergo close ultrasound monitoring. The modest relapse risk, manageable with salvage therapy, must be weighed against the toxicity of prolonged treatment, especially in infants. Both primary and delayed surgery are viable strategies.
- 13 March 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- p. JCO2501755
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study
PURPOSE: The International Society of Paediatric Oncology–Renal Tumour Study Group (SIOP-RTSG) classifies blastemal-type Wilms tumor (WT) after preoperative chemotherapy as high-risk (HRWT). It remains unresolved whether residual absolute volume of blastema (AVB) functions as an independent prognostic factor across WT subtypes. MATERIALS AND METHODS: AVB was calculated from preoperative tumor volume, necrosis percentage, and viable blastema using prospectively collected data from 3,459 patients with unilateral WT treated in the SIOP WT 2001 study between 2001 and 2018. Martingale residual plots defined AVB thresholds discriminating survival in localized HRWT, intermediate-/low-risk WT (IRWT/LRWT), and metastatic WT (stage IV). Complete AVB data were available for 1,802 patients (51.2%); 298 (16.5%) had stage IV disease. Of 1,504 patients with localized WT, 265 (17.6%) had HRWT, 1,203 (79.9%) had IRWT, and 36 (2.4%) had LRWT. RESULTS: Multivariable Cox regression adjusted for age, sex, and local stage confirmed significantly worse survival for patients exceeding these AVB thresholds: (1) IRWT (≥20 mL): Hazard ratio for event-free survival (EFS) 2.93 (95% CI, 2.08 to 4.12) and overall survival (OS) 2.76 (95% CI, 1.32 to 5.77); (2) HRWT (≥100 mL): EFS 2.89 (95% CI, 1.59 to 5.26) and OS 3.25 (95% CI, 1.45 to 7.27); and (3) stage IV (≥10 mL): EFS 5.78 (95% CI, 3.65 to 9.17) and OS 4.59 (95% CI, 2.57 to 8.17). Patients above these thresholds had significantly lower 2-year EFS ( P < .0001). In stage II to III IRWT patients with AVB ≥20 mL, those treated with doxorubicin had superior EFS versus those without (87.6%, 95% CI, 81.5 to 94.1 v 69.2%, 95% CI, 59.8 to 80.1; P = .0064). CONCLUSION: AVB after preoperative chemotherapy is a strong, independent predictor of both EFS and OS in WT across risk groups. An AVB of ≥20 mL identifies a clinically relevant subset of patients with IRWT who may benefit from intensified therapy with doxorubicin. These findings support the use of AVB as a stratification criterion in future SIOP-RTSG protocols.
- 13 March 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- p. JCO2501755
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study
PURPOSE: The International Society of Paediatric Oncology–Renal Tumour Study Group (SIOP-RTSG) classifies blastemal-type Wilms tumor (WT) after preoperative chemotherapy as high-risk (HRWT). It remains unresolved whether residual absolute volume of blastema (AVB) functions as an independent prognostic factor across WT subtypes. MATERIALS AND METHODS: AVB was calculated from preoperative tumor volume, necrosis percentage, and viable blastema using prospectively collected data from 3,459 patients with unilateral WT treated in the SIOP WT 2001 study between 2001 and 2018. Martingale residual plots defined AVB thresholds discriminating survival in localized HRWT, intermediate-/low-risk WT (IRWT/LRWT), and metastatic WT (stage IV). Complete AVB data were available for 1,802 patients (51.2%); 298 (16.5%) had stage IV disease. Of 1,504 patients with localized WT, 265 (17.6%) had HRWT, 1,203 (79.9%) had IRWT, and 36 (2.4%) had LRWT. RESULTS: Multivariable Cox regression adjusted for age, sex, and local stage confirmed significantly worse survival for patients exceeding these AVB thresholds: (1) IRWT (≥20 mL): Hazard ratio for event-free survival (EFS) 2.93 (95% CI, 2.08 to 4.12) and overall survival (OS) 2.76 (95% CI, 1.32 to 5.77); (2) HRWT (≥100 mL): EFS 2.89 (95% CI, 1.59 to 5.26) and OS 3.25 (95% CI, 1.45 to 7.27); and (3) stage IV (≥10 mL): EFS 5.78 (95% CI, 3.65 to 9.17) and OS 4.59 (95% CI, 2.57 to 8.17). Patients above these thresholds had significantly lower 2-year EFS ( P < .0001). In stage II to III IRWT patients with AVB ≥20 mL, those treated with doxorubicin had superior EFS versus those without (87.6%, 95% CI, 81.5 to 94.1 v 69.2%, 95% CI, 59.8 to 80.1; P = .0064). CONCLUSION: AVB after preoperative chemotherapy is a strong, independent predictor of both EFS and OS in WT across risk groups. An AVB of ≥20 mL identifies a clinically relevant subset of patients with IRWT who may benefit from intensified therapy with doxorubicin. These findings support the use of AVB as a stratification criterion in future SIOP-RTSG protocols.
- Open Access
- 7 March 2026
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 11 (1)
High-grade surface Osteosarcoma – Data from the Cooperative Osteosarcoma Study Group (COSS)
- 7 March 2026
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 11 (1)
Open AccessHigh-grade surface Osteosarcoma – Data from the Cooperative Osteosarcoma Study Group (COSS)
- Open Access
Consensus recommendations in the management of jaw (gnathic) osteosarcoma
Gnathic osteosarcoma (OS), which includes mandibular and maxillary jaw OSs, account for 6%–9% of OS. Single‐institutional and multi‐institutional retrospective studies, as well as population‐level databases, suggest that clinical differences exist among gnathic OS and OS of other sides, including other craniofacial OS. To date, no specific prospective studies of gnathic OS have been reported, and aspects of clinical management are controversial. Some elements of care are aligned with extragnathic OS, e.g., margin negative (R0) surgery, whereas others, such as chemotherapy and radiation, are not clearly defined. The authors reviewed the available literature for the diagnosis, treatment, and supportive/survivorship care patients with gnathic OS and offer consensus statements for the comprehensive management of this rare disease.
Open AccessConsensus recommendations in the management of jaw (gnathic) osteosarcoma
Gnathic osteosarcoma (OS), which includes mandibular and maxillary jaw OSs, account for 6%–9% of OS. Single‐institutional and multi‐institutional retrospective studies, as well as population‐level databases, suggest that clinical differences exist among gnathic OS and OS of other sides, including other craniofacial OS. To date, no specific prospective studies of gnathic OS have been reported, and aspects of clinical management are controversial. Some elements of care are aligned with extragnathic OS, e.g., margin negative (R0) surgery, whereas others, such as chemotherapy and radiation, are not clearly defined. The authors reviewed the available literature for the diagnosis, treatment, and supportive/survivorship care patients with gnathic OS and offer consensus statements for the comprehensive management of this rare disease.
- Top Cited PapersOpen Access
- 20 January 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (1) , 40
Undifferentiated pleomorphic sarcoma of bone (UPSB) treated in the German-speaking countries. A report of 132 unselected patients from the Cooperative Osteosarcoma Study Group (COSS)
Purpose: To describe Undifferentiated Pleomorphic Sarcoma of Bone (UPSB) treated in Germany, Austria, or Switzerland and using the same treatment-approach as for osteosarcoma. Patients and methods: The database of the Cooperative Osteosarcoma Study Group (COSS) was screened for UPSB. Eligible patients were evaluated for patient, tumor, and treatment related variables, and outcomes. Results: One-hundred thirty-two eligible patients were identified (median age 41.7 (range: 10.3–74.6) years; males 58%; preceding malignancies 11%; tumor-sites extremities 86%, trunk 12%, head & neck 2%). Relative tumor size was < 1/3 of the involved bone in 83% of evaluable cases, pathologic fractures were present in 14% (limb-primaries only), and primary distant metastases in 6%. All patients received chemotherapy and 96% surgery for their primary (81% limb-salvage for extremity lesions). The response rate to preoperative chemotherapy was 38%. After a median follow-up of 3.9 (1 day–34.1) years for event-free and 5.2 (0.2–34.1) years for overall survival, the 5 year event-free and overall survival probabilities were 63% (standard error: 5%) and 70% (4%), respectively. Younger patient age, an extremity tumor, and localized disease predicted superior outcomes, pathologic fractures and limb-salvage surgery worse. The extent of tumor response to pre-operative chemotherapy seemed to have no impact on prognosis. Discussion: UPSB generally affects considerably older persons than does the more frequent osteosarcoma. Despite a lower response rate to preoperative chemotherapy, its prognosis is at least comparable, if not better. Several prognostic factors impacting outcome could be defined. These results provide a benchmark for this rare disease.
- 20 January 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (1) , 40
Top Cited PapersOpen AccessUndifferentiated pleomorphic sarcoma of bone (UPSB) treated in the German-speaking countries. A report of 132 unselected patients from the Cooperative Osteosarcoma Study Group (COSS)
Purpose: To describe Undifferentiated Pleomorphic Sarcoma of Bone (UPSB) treated in Germany, Austria, or Switzerland and using the same treatment-approach as for osteosarcoma. Patients and methods: The database of the Cooperative Osteosarcoma Study Group (COSS) was screened for UPSB. Eligible patients were evaluated for patient, tumor, and treatment related variables, and outcomes. Results: One-hundred thirty-two eligible patients were identified (median age 41.7 (range: 10.3–74.6) years; males 58%; preceding malignancies 11%; tumor-sites extremities 86%, trunk 12%, head & neck 2%). Relative tumor size was < 1/3 of the involved bone in 83% of evaluable cases, pathologic fractures were present in 14% (limb-primaries only), and primary distant metastases in 6%. All patients received chemotherapy and 96% surgery for their primary (81% limb-salvage for extremity lesions). The response rate to preoperative chemotherapy was 38%. After a median follow-up of 3.9 (1 day–34.1) years for event-free and 5.2 (0.2–34.1) years for overall survival, the 5 year event-free and overall survival probabilities were 63% (standard error: 5%) and 70% (4%), respectively. Younger patient age, an extremity tumor, and localized disease predicted superior outcomes, pathologic fractures and limb-salvage surgery worse. The extent of tumor response to pre-operative chemotherapy seemed to have no impact on prognosis. Discussion: UPSB generally affects considerably older persons than does the more frequent osteosarcoma. Despite a lower response rate to preoperative chemotherapy, its prognosis is at least comparable, if not better. Several prognostic factors impacting outcome could be defined. These results provide a benchmark for this rare disease.
- Open Access
- 9 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32111
Efficacy of Preoperative Chemotherapy in Patients With Nephroblastoma and Imaging Findings Suggestive of Preoperative Tumor Rupture
Background and Aims: If Wilms tumor (WT) rupture is suspected preoperatively, it is unclear whether preoperative chemotherapy (preop‐CT) can be safely given and whether such patients need to be treated according to local stage III postoperatively. Methods: We retrospectively analyzed characteristics, treatment, and outcome of patients with preoperative rupture suspected by imaging and clinical symptoms in 119 patients from Germany, Austria, and Switzerland with unilateral WT treated within SIOP studies. Results: There was no difference in age and gender distribution compared with the overall cohort of patients with WT. The general health condition was characterized at least severely impaired (37.8%). Eighty‐nine patients 89 (74.8%) received preop‐CT and 30 (25.2%) had upfront surgery. The mean tumor volume at diagnosis undergoing preop‐CT was 605 mL compared with 312 mL at primary surgery. Metastases were found in 20 out of 89 (22.5%) and two out of 30 (6.7%) patients, respectively. After preop‐CT, 31 patients (34.8%) had local histological stage I, 16 (18.0%) had stage II, 41 (46.1%) had stage III, and one (1.1%) had unknown. Low risk histology was diagnosed in seven (7.9%), intermediate risk in 65 (73.0%), and high risk in 17 (19.1%) patients. After preop‐CT, nine patients relapsed (10.1%), compared with four (13.3%) after primary surgery. Relapses were independent of local radiotherapy. Altogether seven patients died. A total of 14 out of 31 patients (45.2%) with overall local stage I of intermediate risk after preop‐CT received only 4 weeks AV without radiotherapy after surgery with 100% relapse‐free survival. Conclusions: Preop‐CT can be given safely, and postoperative treatment can follow the histological staging and risk group, given that a thorough review of the specific situation is done.
- 9 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (1) , e32111
Open AccessEfficacy of Preoperative Chemotherapy in Patients With Nephroblastoma and Imaging Findings Suggestive of Preoperative Tumor Rupture
Background and Aims: If Wilms tumor (WT) rupture is suspected preoperatively, it is unclear whether preoperative chemotherapy (preop‐CT) can be safely given and whether such patients need to be treated according to local stage III postoperatively. Methods: We retrospectively analyzed characteristics, treatment, and outcome of patients with preoperative rupture suspected by imaging and clinical symptoms in 119 patients from Germany, Austria, and Switzerland with unilateral WT treated within SIOP studies. Results: There was no difference in age and gender distribution compared with the overall cohort of patients with WT. The general health condition was characterized at least severely impaired (37.8%). Eighty‐nine patients 89 (74.8%) received preop‐CT and 30 (25.2%) had upfront surgery. The mean tumor volume at diagnosis undergoing preop‐CT was 605 mL compared with 312 mL at primary surgery. Metastases were found in 20 out of 89 (22.5%) and two out of 30 (6.7%) patients, respectively. After preop‐CT, 31 patients (34.8%) had local histological stage I, 16 (18.0%) had stage II, 41 (46.1%) had stage III, and one (1.1%) had unknown. Low risk histology was diagnosed in seven (7.9%), intermediate risk in 65 (73.0%), and high risk in 17 (19.1%) patients. After preop‐CT, nine patients relapsed (10.1%), compared with four (13.3%) after primary surgery. Relapses were independent of local radiotherapy. Altogether seven patients died. A total of 14 out of 31 patients (45.2%) with overall local stage I of intermediate risk after preop‐CT received only 4 weeks AV without radiotherapy after surgery with 100% relapse‐free survival. Conclusions: Preop‐CT can be given safely, and postoperative treatment can follow the histological staging and risk group, given that a thorough review of the specific situation is done.
- Open Access
- 9 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (17) , e71211
Teleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group ( COSS )
Purpose: Teleangiectatic osteosarcoma is a histologic subtype of osteosarcoma that can mimic aneurysmal bone cysts and has so far been incompletely characterized. Patients and Methods: We used the database of the Cooperative Osteosarcoma Study Group COSS (patient‐registration 1980–2019) to better understand this rare histologic variant. Results: 223 eligible patients were identified, 164 having reference pathology (median age 15.9 (3.7–69.7) years; male 134, female 89; tumor sites limb 208 (201 metaphyses, 66 pathologic fractures), trunk 13, head & neck 2; 26 with primary metastases). Known tumor‐predisposition syndromes were rare. Therapy included surgery in 215, radiotherapy in 10, and chemotherapy in all patients. Tumor response to preoperative treatment was good in 71% of 165 cases with available data. After a median follow‐up of 7.1 (0.2–32.1) years for all patients and 10.5 (0.2–32.1) years for 152 survivors, 5‐/10‐year actuarial event‐free and overall survival expectancies were 61%/57% and 73%/66%, respectively. Five unrelated malignancies occurred during this period. The presence of primary metastases, pathologic fracture, poor response to neoadjuvant chemotherapy, and not obtaining a complete macroscopic remission were associated with inferior outcomes for both event‐free and overall survival ( p < 0.01). Discussion: This large analysis proves teleangiectatic osteosarcoma to be a disease predominantly of the metaphyses of the young. While detected only rarely, the true incidence of genetic tumor predispositions would require prospective assessments. Behaving like other osteosarcoma subtypes in many other ways, this variant may show greater chemosensitivity and hence somewhat better outcomes than other subtypes.
- 9 September 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (17) , e71211
Open AccessTeleangiectatic Osteosarcoma Treated by Surgery and Chemotherapy: A Report of 223 Affected Patients From the Cooperative Osteosarcoma Study Group ( COSS )
Purpose: Teleangiectatic osteosarcoma is a histologic subtype of osteosarcoma that can mimic aneurysmal bone cysts and has so far been incompletely characterized. Patients and Methods: We used the database of the Cooperative Osteosarcoma Study Group COSS (patient‐registration 1980–2019) to better understand this rare histologic variant. Results: 223 eligible patients were identified, 164 having reference pathology (median age 15.9 (3.7–69.7) years; male 134, female 89; tumor sites limb 208 (201 metaphyses, 66 pathologic fractures), trunk 13, head & neck 2; 26 with primary metastases). Known tumor‐predisposition syndromes were rare. Therapy included surgery in 215, radiotherapy in 10, and chemotherapy in all patients. Tumor response to preoperative treatment was good in 71% of 165 cases with available data. After a median follow‐up of 7.1 (0.2–32.1) years for all patients and 10.5 (0.2–32.1) years for 152 survivors, 5‐/10‐year actuarial event‐free and overall survival expectancies were 61%/57% and 73%/66%, respectively. Five unrelated malignancies occurred during this period. The presence of primary metastases, pathologic fracture, poor response to neoadjuvant chemotherapy, and not obtaining a complete macroscopic remission were associated with inferior outcomes for both event‐free and overall survival ( p < 0.01). Discussion: This large analysis proves teleangiectatic osteosarcoma to be a disease predominantly of the metaphyses of the young. While detected only rarely, the true incidence of genetic tumor predispositions would require prospective assessments. Behaving like other osteosarcoma subtypes in many other ways, this variant may show greater chemosensitivity and hence somewhat better outcomes than other subtypes.
- Open Access
- 20 May 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (14)
The NUDIX hydrolase NUDT5 influences purine nucleotide metabolism and thiopurine pharmacology
Purine nucleotides are critical for nucleic acid synthesis, signaling, and cellular metabolism. Thiopurines (TPs), including 6-mercaptopurine and 6-thioguanine, are cornerstone agents for the treatment of acute lymphoblastic leukemia (ALL). TP efficacy and cytotoxicity depend on the metabolism and intracellular activation of TPs, a process influenced by pharmacogenes such as thiopurine-S methyltransferase ( TPMT ) and NUDIX (nucleoside diphosphates linked to moiety-X) hydrolase 15 ( NUDT15 ). In this issue of the JCI , Maillard et al. identified NUDT5 as a determinant of TP pharmacology. They demonstrated that loss of NUDT5 conferred TP resistance by impairing drug activation and DNA damage responses. Metabolomics studies by Maillard and others revealed that NUDT5 may regulate the balance between the de novo purine synthesis and salvage pathways. Clinically, NUDT5 expression variants were associated with altered TP tolerance. These findings position NUDT5 as a key modulator of nucleotide metabolism and TP efficacy, with potential implications for pharmacogenomics-guided therapy optimization in ALL.
- 20 May 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (14)
Open AccessThe NUDIX hydrolase NUDT5 influences purine nucleotide metabolism and thiopurine pharmacology
Purine nucleotides are critical for nucleic acid synthesis, signaling, and cellular metabolism. Thiopurines (TPs), including 6-mercaptopurine and 6-thioguanine, are cornerstone agents for the treatment of acute lymphoblastic leukemia (ALL). TP efficacy and cytotoxicity depend on the metabolism and intracellular activation of TPs, a process influenced by pharmacogenes such as thiopurine-S methyltransferase ( TPMT ) and NUDIX (nucleoside diphosphates linked to moiety-X) hydrolase 15 ( NUDT15 ). In this issue of the JCI , Maillard et al. identified NUDT5 as a determinant of TP pharmacology. They demonstrated that loss of NUDT5 conferred TP resistance by impairing drug activation and DNA damage responses. Metabolomics studies by Maillard and others revealed that NUDT5 may regulate the balance between the de novo purine synthesis and salvage pathways. Clinically, NUDT5 expression variants were associated with altered TP tolerance. These findings position NUDT5 as a key modulator of nucleotide metabolism and TP efficacy, with potential implications for pharmacogenomics-guided therapy optimization in ALL.